Avenue Therapeutics, Inc.
Other OTCTotal Valuation
Avenue Therapeutics, Inc. carries a market capitalization of 1.42M, placing it among publicly traded companies globally. Its enterprise value stands at -1.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.42M |
| Enterprise Value | -1.02M |
Share Statistics
Avenue Therapeutics, Inc. currently has 3.29M shares outstanding.
| Shares Outstanding | 3.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | -0.66 |
| P/OCF Ratio | -0.66 |
Financial Position
Avenue Therapeutics, Inc. maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.40 |
| Quick Ratio | 1.38 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -120.03 |
| Return on Assets (ROA) | -90.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Avenue Therapeutics, Inc.'s stock has declined approximately -50.05401% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50.05401% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.36 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -3.10M, while operating income came in at -3.10M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -3.10M |
| Pretax Income | -2.80M |
| Net Income | -2.78M |
| EBITDA | -3.10M |
| EBIT | -3.10M |
| Earnings Per Share (EPS) | -0.86 |
Balance Sheet
Total book value stands at 569,000.00, with working capital of 569,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.94M |
| Total Debt | N/A |
| Net Debt | -1.94M |
| Equity (Book Value) | 569,000.00 |
| Book Value Per Share | 0.17 |
| Working Capital | 569,000.00 |
Cash Flow
Avenue Therapeutics, Inc. produced -1.38M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.38M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.38M |
| FCF Per Share | -0.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -151.74 |
Stock Splits
Avenue Therapeutics, Inc.'s most recent stock split took place on April 26, 2024 with a 75:1 split ratio.
| Last Split Date | 4/26/2024 |
| Split Ratio | 75:1 |
Scores
Avenue Therapeutics, Inc. posts an Altman Z-Score of -80.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -80.16 |